Topic Systematic review of risk factors for nonadherence and nonpersistence to intravitreal
anti–vascular endothelial growth factor (VEGF) injection therapy for neovascular age-related …

Purpose: To assess the gap between visual acuity (VA) outcomes with anti-vascular
endothelial growth factor (anti-VEGF) therapies in clinical trials and real-world practice, and …

Purpose Two similarly designed phase 3 trials (HAWK and HARRIER) compared
brolucizumab, a single-chain antibody fragment that inhibits vascular endothelial growth …

Background Brolucizumab has recently been approved in Europe as a novel treatment for
patients with neovascular age-related macular degeneration (nAMD). We report on early …

Purpose Real-life clinical outcomes of patients treated with anti-VEGF drugs for neovascular
age-related macular degeneration (nAMD), diabetic macular edema (DME), or macular …

Inhibition of vascular endothelial growth factor, a key contributor to the choroidal
neovascularization associated with wet age-related macular degeneration, is the mode of …

Background Intravitreal aflibercept 8 mg could improve treatment outcomes and provide
sustained disease control in patients with neovascular age-related macular degeneration …

Importance Loss to follow-up (LTFU) after anti–vascular endothelial growth factor (anti-
VEGF) injections increases the risk of vision loss among patients with neovascular age …

Molecular medicine has entered a high-tech age that provides curative treatments of
complex genetic diseases through genetically engineered cellular medicinal products. Their …

Purpose The coronavirus pandemic has prompted unprecedented delays to treatment with
anti-VEGF intravitreal injections due to the need to reduce hospital attendances and …